WhiteSwell has developed the eLym™ System, which creates a low-pressure zone at the thoracic duct outlet to enhance lymphatic drainage during acute decompensated heart failure (ADHF). This approach directly targets tissue and organ congestion, addressing the limitations of current therapies that primarily focus on vascular congestion.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with acute decompensated heart failure (ADHF) experience tissue and organ congestion, leading to symptoms like leg swelling and difficulty breathing. Current treatments primarily target vascular congestion and do not directly address the excess fluid accumulation in tissues, which can lead to persistent congestion and poor outcomes. The lymphatic system, responsible for draining fluid from tissues, becomes overwhelmed in ADHF, exacerbating edema.
Solution
WhiteSwell's eLym™ System is designed to enhance lymphatic drainage in patients with ADHF by creating a low-pressure zone at the thoracic duct outlet. This approach aims to reduce resistance to lymphatic drainage, facilitating the removal of excess fluid from tissues and organs. By directly targeting tissue congestion, the eLym™ System complements existing therapies that primarily focus on vascular congestion. The system supports the body's natural ability to maintain fluid balance, potentially improving decongestion and patient outcomes.
Target Audience
The primary target audience includes patients suffering from acute decompensated heart failure (ADHF) and the medical professionals treating this condition.
Features
- eLym™ System creates a low-pressure zone at the thoracic duct outlet.
- Designed to reduce resistance to lymphatic drainage.
- Aims to directly target tissue and organ congestion.